SIETES :: 93213 citas

Resultados de la búsqueda por AMGEN REFINAR BÚSQUEDA

1.

Taylor P. BMS completes Celgene merger after FTC okay. PMLiVE 2019:18 de noviembre. [Ref.ID 103210]

2.

Anónimo. Amgen unlikely to launch adalimumab biosimilar in 2017 due to litigation. DIA Daily 2016:6. [Ref.ID 100871]

3.

Anónimo. FDA approves biosimilar version of adalimumab, but legal obstacles remain. DIA Daily 2016:1. [Ref.ID 100719]

4.

Anónimo. Erenumab helps reduce incidence of chronic migraines, clinical trial suggests. DIA Daily 2016:4. [Ref.ID 100675]

5.

Anónimo. Biosimilar version of trastuzumab demonstrates non-inferiority in phase III clinical trial. DIA Daily 2016;22 de julio:2. [Ref.ID 100506]

6.

Anónimo. FDA declines to approve biosimilar version of pegfilgrastim. DIA Daily 2016:1. [Ref.ID 100499]

7.

Anónimo. Drugmakers using new patents to delay introduction of biosimilars. DIA Daily 2016:6. [Ref.ID 100496]

8.

Anónimo. FDA advisory panel unanimously recommends approval Of biosimilar version of adalimumab. DIA Daily 2016:1. [Ref.ID 100493]

9.

Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016;388:45-54. [Ref.ID 100482]

10.

Chaturvedi S, McCrae KR. Treatment of chronic immune thrombocytopenia in children with romiplostim. Lancet 2016;388:4-6. [Ref.ID 100480]

11.

Anónimo. UK’s NICE recommends against Sanofi’s cholesterol drug, backs Amgen’s. DIA Daily 2016:1. [Ref.ID 99995]

12.

Young K. FDA advisers recommend first-in-class cholesterol-lowering meds. Journal Watch 2015:11 de junio. [Ref.ID 99172]

13.

Anónimo. Amgen ends partnership with AstraZeneca due to safety concerns with drug. DIA Daily 2015:26 de mayo. [Ref.ID 99095]

14.

Anónimo. Pharmaceutical giant’s plea to block rival’s filgrastim biosimilar rejected. DIA Daily 2015:20 de marzo. [Ref.ID 98863]

15.

Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ 2013;346:23-6. [Ref.ID 95962]

16.

Schroll JB, Bero L, Gotzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ 2013;346:12. [Ref.ID 95960]

17.

Loder E, Godlee F, Barbour V, Winker M. Restoring the integrity of the clinical trial evidence base. BMJ 2013;346:7. [Ref.ID 95959]

18.

Anónimo. Onyx, Amgen reach $10.4B deal. DIA Daily 2013:26 de agosto. [Ref.ID 95895]

19.

Epstein K. Full results on risk of epoetin emerge 14 years after study. BMJ 2012;344:2. [Ref.ID 92999]

20.

Anónimo. FDA approves peginesatide for anemia. DIA Daily 2012:28 de marzo. [Ref.ID 92479]